O12: Real world impact of germline genetic testing on clinical decision making for prostate cancer patients*

• Neal Shore,
• Christopher Pieczonka,
• Mukaram Gazi,
• Sean Heron,
• David Cahn,
• Laurence Belkoff,
• Aaron Berger,
• Brian Mazzarella,
• Joseph Veys,
• David Morris,
• Alexander Engelman,
• Paul Dato,
• Richard Bevan-Thomas,
• Kathryn Hatchell,
• Robert Cornell,
• David R. Wise,
• Brandie Heald,
• Sarah Nielsen (Young),
• Robert Nussbaum,
• Edward Esplin

Affiliations

Neal Shore

Carolina Urologic Research Center, Myrtle Beach, SC

Christopher Pieczonka

Associated Medical Professionals, Syracuse, NY

Mukaram Gazi

University Urology Associates of New Jersey, Hamilton, NJ

Sean Heron

Advanced Urology Institute, St. Petersburg, FL

David Cahn

Colorado Urology, Lakewood, CO

Laurence Belkoff

MidLantic Urology, Bala Cynwyd, PA

Aaron Berger

Associated Urological Specialists, Chicago Ridge, IL

Brian Mazzarella

Urology Austin, Austin, TX

Joseph Veys

North Georgia Urology, Dalton, GA

David Morris

Urology Associates, P.C., Nashville, TN

Alexander Engelman

Florida Urology Partners, Cancer Center of South Tampa, St. Petersburg, FL

Paul Dato

Genesis Healthcare Partners, San Diego, CA

Richard Bevan-Thomas

Urology Partners, Arlington, TX

Kathryn Hatchell

Invitae

Robert Cornell

Urosurgery Houston, Houston, TX

David R. Wise

Perlmutter Cancer Center

Brandie Heald

Invitae

Sarah Nielsen (Young)

Invitae

Robert Nussbaum

Invitae

Edward Esplin

Invitae